Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Affimed (GB:0HL9)
LSE:0HL9
Holding GB:0HL9?
Track your performance easily
0HL9 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.15 - $8.90
Previous Close$1.19
Volume41.24K
Average Volume (3M)8.95K
Market Cap
$17.97M
Enterprise Value-$37.37M
Total Cash (Recent Filing)€72.05M
Total Debt (Recent Filing)€19.35M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Mar 27, 2025EPS Estimate
-$0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.35
Shares Outstanding15,227,463
10 Day Avg. Volume34,788
30 Day Avg. Volume8,949
Standard Deviation0.23
R-Squared0.21
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.74
Price to Sales (P/S)1.95
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.75Price Target Upside467.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Affimed News
PremiumCompany Announcements
Affimed’s Promising Clinical Update on NSCLC Treatment
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAFM24 showed more durable benefit than standard of care in EGFR wild-type patients.
Investor InterestEarly signs of durability in this year’s datasets could drive upside in the very underappreciated AFMD stock.
Partnership OpportunitiesAffimed’s three active molecules should be of interest to pharma, and a partnership with non-dilutive financing would provide significant support for the stock.
Bears Say
Clinical DataThe clinical updates for AFM28 and acimtamig + AB101 were too early to draw important conclusions on durability of benefit.
Financial PerformanceProlonged timelines to more robust and interpretable dose expansion catalysts introduce extend the overhang for the stock, especially given the company’s restricting cash position.
Safety ConcernsCRS was reported in 27% of patients, with one case being Grade 3, which is a safety concern.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.48% Mutual Funds
10.25% Other Institutional Investors
88.18% Public Companies and
Individual Investors
0HL9 FAQ
What was Affimed’s price range in the past 12 months?
Affimed lowest share price was $1.15 and its highest was $8.89 in the past 12 months.
What is Affimed’s market cap?
Currently, no data Available
When is Affimed’s upcoming earnings report date?
Affimed’s upcoming earnings report date is Mar 27, 2025 which is in 95 days.
How were Affimed’s earnings last quarter?
Affimed released its earnings results on Nov 14, 2024. The company reported -$0.987 earnings per share for the quarter, missing the consensus estimate of -$0.969 by -$0.018.
Is Affimed overvalued?
According to Wall Street analysts Affimed’s price is currently Undervalued.
Does Affimed pay dividends?
Affimed does not currently pay dividends.
What is Affimed’s EPS estimate?
Affimed’s EPS estimate is -$0.75.
How many shares outstanding does Affimed have?
Affimed has 15,227,463 shares outstanding.
What happened to Affimed’s price movement after its last earnings report?
Affimed reported an EPS of -$0.987 in its last earnings report, missing expectations of -$0.969. Following the earnings report the stock price went up 1.964%.
Which hedge fund is a major shareholder of Affimed?
Among the largest hedge funds holding Affimed’s share is Baker Bros Advisors LP. It holds Affimed’s shares valued at N/A.
---
Affimed Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.75 (467.23% Upside)
$6.75 (467.23% Upside)
Blogger Sentiment
Bullish
GB:0HL9 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.51%
12-Months-Change
Fundamentals
Return on Equity
-151.46%
Trailing 12-Months
Asset Growth
-65.03%
Trailing 12-Months
Company Description
Affimed
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
---
0HL9 Company Deck
---
0HL9 Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials, particularly with AFM24 and AFM28, and a strategic focus on partnerships and financial health. However, there were notable challenges, including a decline in revenue and reduced cash reserves. Despite these challenges, the company's efforts to improve its financial position and strategic focus are promising.Read More>---
0HL9 Stock 12 Month Forecast
Average Price Target
$6.75
▲(467.23% Upside)
Technical Analysis
Affimed
―
Adaptimmune Therapeutics
―
Immutep
―
Karyopharm Therapeutics
―
Kura Oncology
―
Best Analysts Covering 0HL9
1 Year
1 Year Success Rate
1/11 ratings generated profit
1 Year Average Return
-49.86%
assigned a buy rating 4 days ago
Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -49.86% per trade.
---